Related Experiment Video
Updated: Apr 28, 2026

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
Published on: June 4, 2021
Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective
David G Twigg1, Kenta Arai1, Michelle R Arkin2
1Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K.
Abstract:
Fragment-based drug discovery (FBDD) has led to dozens of clinical compounds, including eight approved drugs. For the past decade, we have published an annual review of successful fragment-to-lead (F2L) medicinal chemistry programs. This Perspective marks the tenth in the series. We analyze the 18 F2L case studies from 2024 and put them in the context of the larger set of 233 examples dating back to 2015. We hope that the lessons herein will both inform and inspire researchers to discover the next generation of drugs.
Related Concept Videos
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
Drug Discovery: Overview
Preclinical Development: Overview
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

